scholarly journals HIV-1/AIDS vaccine development: are we in the darkness before the dawn?

2008 ◽  
Vol 121 (10) ◽  
pp. 939-945 ◽  
Author(s):  
Chao QIU ◽  
Jian-qing XU
Keyword(s):  
Vaccine Development ◽  
Aids Vaccine ◽  
Hiv 1

HIV-1 Tat-Based Vaccines: An Overview and Perspectives in the Field of HIV/AIDS Vaccine Development

2009 ◽  
Vol 28 (5) ◽  
pp. 285-334 ◽  
Author(s):  
Antonella Caputo ◽  
Riccardo Gavioli ◽  
Stefania Bellino ◽  
Olimpia Longo ◽  
Antonella Tripiciano ◽  
...  
Keyword(s):  
Vaccine Development ◽  
Aids Vaccine ◽  
Hiv 1 ◽  
Hiv Aids

scholarly journals HIV-1 genetic diversity a challenge for AIDS vaccine development: a retrospective bibliometric analysis

2022 ◽  
pp. 1-11
Author(s):  
Abdur Rashid ◽  
Kang Li ◽  
Yi Feng ◽  
Tauseef Ahmad ◽  
Yimam Getaneh ◽  
...  
Keyword(s):  
Genetic Diversity ◽  
Bibliometric Analysis ◽  
Vaccine Development ◽  
Aids Vaccine ◽  
Hiv 1

scholarly journals Characterization of Primary Isolate-Like Variants of Simian-Human Immunodeficiency Virus

1999 ◽  
Vol 73 (12) ◽  
pp. 10199-10207 ◽  
Author(s):  
John M. Crawford ◽  
Patricia L. Earl ◽  
Bernard Moss ◽  
Keith A. Reimann ◽  
Michael S. Wyand ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Mononuclear Cells ◽  
Vaccine Development ◽  
Envelope Glycoproteins ◽  
Serum Samples ◽  
Aids Vaccine ◽  
Antigenic Properties ◽  
Immunodeficiency Virus ◽  
Hiv 1 ◽  
Soluble Cd4

ABSTRACT Several different strains of simian-human immunodeficiency virus (SHIV) that contain the envelope glycoproteins of either T-cell-line-adapted (TCLA) strains or primary isolates of human immunodeficiency virus type 1 (HIV-1) are now available. One of the advantages of these chimeric viruses is their application to studies of HIV-1-specific neutralizing antibodies in preclinical AIDS vaccine studies in nonhuman primates. In this regard, an important consideration is the spectrum of antigenic properties exhibited by the different envelope glycoproteins used for SHIV construction. The antigenic properties of six SHIV variants were characterized here in neutralization assays with recombinant soluble CD4 (rsCD4), monoclonal antibodies, and serum samples from SHIV-infected macaques and HIV-1-infected individuals. Neutralization of SHIV variants HXBc2, KU2, 89.6, and 89.6P by autologous and heterologous sera from SHIV-infected macaques was restricted to an extent that these viruses may be considered heterologous to one another in their major neutralization determinants. Little or no variation was seen in the neutralization determinants on SHIV variants 89.6P, 89.6PD, and SHIV-KB9. Neutralization of SHIV HXBc2 by sera from HXBc2-infected macaques could be blocked with autologous V3-loop peptide; this was less true in the case of SHIV 89.6 and sera from SHIV 89.6-infected macaques. The poorly immunogenic but highly conserved epitope for monoclonal antibody IgG1b12 was a target for neutralization on SHIV variants HXBc2, KU2, and 89.6 but not on 89.6P and KB9. The 2G12 epitope was a target for neutralization on all five SHIV variants. SHIV variants KU2, 89.6, 89.6P, 89.6PD, and KB9 exhibited antigenic properties characteristic of primary isolates by being relatively insensitive to neutralization in peripheral blood mononuclear cells with serum samples from HIV-1-infected individuals and 12-fold to 38-fold less sensitive to inhibition with recombinant soluble CD4 than TCLA strains of HIV-1. The utility of nonhuman primate models in AIDS vaccine development is strengthened by the availability of SHIV variants that are heterologous in their neutralization determinants and exhibit antigenic properties shared with primary isolates.

scholarly journals Generation of a Consensus Sequence from Prevalent and Incident HIV-1 Infections in West Africa to Guide AIDS Vaccine Development

Virology ◽  
2002 ◽  
Vol 302 (1) ◽  
pp. 155-163 ◽  
Author(s):  
Dennis L Ellenberger ◽  
Bin Li ◽  
L.Davis Lupo ◽  
S.Michele Owen ◽  
John Nkengasong ◽  
...  
Keyword(s):  
West Africa ◽  
Vaccine Development ◽  
Consensus Sequence ◽  
Aids Vaccine ◽  
Hiv 1

Peptide–MHC multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS vaccine development

2014 ◽  
Vol 14 (1) ◽  
pp. 69-84 ◽  
Author(s):  
Alena Y Reguzova ◽  
Larisa I Karpenko ◽  
Ludmila V Mechetina ◽  
Igor M Belyakov
Keyword(s):  
T Cells ◽  
Cd8 T Cells ◽  
Vaccine Development ◽  
Aids Vaccine ◽  
Hiv 1 ◽  
Mhc Multimer

Short Oligopeptide T-Cell Epitopes in HIV-1/AIDS Vaccine Development: Current Status, Design, Promises and Challenges

2017 ◽  
pp. 925-938
Author(s):  
Pandjassarame Kangueane ◽  
Kumar Viswapoorani ◽  
Christina Nilofer ◽  
Subramani Manimegalai ◽  
Murugan Sivagamy ◽  
...  
Keyword(s):  
T Cell ◽  
Vaccine Development ◽  
Current Status ◽  
T Cell Epitopes ◽  
Aids Vaccine ◽  
Hiv 1

HIV-1 Accessory Proteins: Which one is Potentially Effective in Diagnosis and Vaccine Development?

2020 ◽  
Vol 28 ◽  
Author(s):  
Alireza Milani ◽  
Kazem Baesi ◽  
Elnaz Agi ◽  
Ghazal Marouf ◽  
Maryam Ahmadi ◽  
...  
Keyword(s):  
Immune Response ◽  
Vaccine Development ◽  
Treated Group ◽  
Vaccine Antigen ◽  
Accessory Proteins ◽  
Serological Method ◽  
Th2 Immune Response ◽  
Untreated Individuals ◽  
Immunogenic Properties ◽  
Hiv 1

Background:: The combination antiretroviral therapy (cART) could increase the number of circulating naive CD4 T lymphocytes, but was not able to eradicate human immunodeficiency virus-1 (HIV-1) infection. Objective:: Thus, induction of strong immune responses is important for control of HIV-1 infection. Furthermore, a simple and perfect serological method is required to detect virus in untreated-, treated- and drug resistant- HIV-1 infected individuals. Methods:: This study was conducted to assess and compare immunogenic properties of Nef, Vif, Vpr and Vpu accessory proteins as an antigen candidate in mice and their diagnostic importance in human as a biomarker. Results:: Our data showed that in mice, all heterologous prime/ boost regimens were more potent than homologous prime/ boost regimens in eliciting Th1 response and Granzyme B secretion as CTL activity. Moreover, the Nef, Vpu and Vif proteins could significantly increase Th1 immune response. In contrast, the Vpr protein could considerably induce Th2 immune response. On the other hand, among four accessory proteins, HIV-1 Vpu could significantly detect treated group from untreated group as a possible biomarker in human. Conclusion:: Generally, among accessory proteins, Nef, Vpu and Vif antigens were potentially more suitable vaccine antigen candidates than Vpr antigen. Human antibodies against all these proteins were higher in HIV-1 different groups than healthy group. Among them, Vpu was known as a potent antigen in diagnosis of treated from untreated individuals. The potency of accessory proteins as an antigen candidate in an animal model and a human cohort study are underway.

Live Recombinant Vectors for AIDS Vaccine Development

2003 ◽  
Vol 3 (3) ◽  
pp. 273-284 ◽  
Author(s):  
Rebecca Voltan ◽  
Marjorie Robert-Guroff
Keyword(s):  
Vaccine Development ◽  
Aids Vaccine ◽  
Recombinant Vectors
Sign in / Sign up

Export Citation Format

Share Document